Business Description
Redhill Biopharma Ltd
ISIN : US7574681034
Share Class Description:
STU:2RH: ADRTotal Employee Number:
23Description
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.71 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | -0.14 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -24.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -95.5 | |||||
3-Year EBITDA Growth Rate | 81.1 | |||||
3-Year EPS without NRI Growth Rate | 93.6 | |||||
3-Year FCF Growth Rate | 81.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.34 | |||||
Quick Ratio | 0.34 | |||||
Cash Ratio | 0.21 | |||||
Days Inventory | 804.35 | |||||
Days Sales Outstanding | 3389.65 | |||||
Days Payable | 1144.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -279.7 | |||||
Shareholder Yield % | -184.51 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -461.89 | |||||
Operating Margin % | -2765.39 | |||||
Net Margin % | -150 | |||||
EBITDA Margin % | -2675.52 | |||||
FCF Margin % | -2798.32 | |||||
OCF Margin % | -2796.97 | |||||
ROA % | -2.08 | |||||
ROIC % | -37.72 | |||||
3-Year ROIIC % | -16.57 | |||||
ROC (Joel Greenblatt) % | -1320.75 | |||||
ROCE % | -829.32 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 1.14 | |||||
PE Ratio without NRI | 1.14 | |||||
PS Ratio | 0.58 | |||||
PB Ratio | 0.99 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-Forward-EBITDA | 107.82 | |||||
EV-to-Revenue | 4.92 | |||||
EV-to-Forward-Revenue | 1.42 | |||||
EV-to-FCF | -0.15 | |||||
Earnings Yield (Greenblatt) % | -588.39 | |||||
FCF Yield % | -224.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Redhill Biopharma Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.297 | ||
| EPS (TTM) (€) | 0.621 | ||
| Beta | 5.2409 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.49 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 8.2375 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 8.2375 - 8.2375 | ||
| Shares Outstanding (Mil) | 5.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Redhill Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Redhill Biopharma Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-09-04 | In 64 days | ||
| General meeting for 2026 | 2026-07-06 | In 4 days | ||
| Annual report for 2025 | 2026-04-27 | 8.24 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-27 | 8.24 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-05 | 8.24 (+0.00%) | ||
| General meeting for 2025 | 2025-05-05 15:00 | 8.24 (+0.00%) | ||
| Annual report for 2024 | 2025-04-10 | 8.24 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-10 | 8.24 (+0.00%) | ||
| 18th Annual European Life Sciences CEO Forum | 2025-02-27 11:00 | 8.24 (+0.00%) |
Show
Entries
Redhill Biopharma Ltd Frequently Asked Questions
What is Redhill Biopharma Ltd(STU:2RH)'s stock price today?
The current price of STU:2RH is €8.24. The 52 week high of STU:2RH is €8.24 and 52 week low is €8.24.
When is next earnings date of Redhill Biopharma Ltd(STU:2RH)?
The next earnings date of Redhill Biopharma Ltd(STU:2RH) is 2026-09-04 Est..
Does Redhill Biopharma Ltd(STU:2RH) pay dividends? If so, how much?
Redhill Biopharma Ltd(STU:2RH) does not pay dividend.
Press Release
Articles on Redhill Biopharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers